Naseema Gangat
Associate Editor at Blood Cancer Journal
Corespodent at Wiley Online Library
Hematologist @MayoClinic Interests MPN #mpnsm, MDS #mdssm, AML #leusm Alumnus @MayoMN_IMRES @MayoHemeOnc @AKUGlobal Tweets my own
Articles
-
4 weeks ago |
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
• , , , et al., “ CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia ,” Journal of Clinical Oncology , no. ( ): – . • , , , et al., “ The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms ,” Leukemia , no. ( ): – .
-
1 month ago |
nature.com | Naseema Gangat |Ayalew Tefferi
Momelotinib, a small-molecule Janus kinase 1 and 2 (JAK1/2) and activin A receptor, type 1 (ACVR1)/activin receptor-like kinase 2 (ALK2) inhibitor, represents an important addition to the treatment armamentarium for myelofibrosis (MF), due to its ability to not only address splenomegaly, and constitutional symptoms but also alleviate anemia [1, 2].
-
1 month ago |
nature.com | Mithun Vinod Shah |Kevin Hung |Anmol Baranwal |Aref Al-Kali |Antoine Saliba |dong chen | +18 more
AbstractThe World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53mut (variant allele frequency, VAF ≥ 2%).
-
2 months ago |
nature.com | Saubia Fathima |Naseema Gangat
Dear Editor,Primary myelofibrosis (PMF) is a myeloid neoplasm that is currently classified in the category of JAK2 mutation-prevalent myeloproliferative neoplasms (JAK2-MPNs) [1]; other members of JAK2-MPNs include essential thrombocythemia (ET) and polycythemia vera (PV).
-
2 months ago |
digitalcommons.library.tmc.edu | Naseema Gangat
AbstractPatients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 313
- DMs Open
- No
Wh(V)en less is more in AML Comment on forthcoming article by Willekens et al ://ashpublications.org/blood/article/140/Supplement%201/537/490259/Reduced-Venetoclax-Exposition-to-Seven-Days-of #amlsm @BloodCancerJnl @MayoCancerCare
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days https://t.co/KHCQoRnwCu
Exapanding the horizon on Ven-HMA in AML-ELN2024 and Mayo Genetic Risk Models #amlsm
Our commentary is out in @AjHematology! "Sharpening the Tools to Get the Edge on Leukemia" with Jacqueline_Garcia on @n_gangat Mayo clinic model (https://t.co/cJxe4YQTBQ) for #AMLsm treated with HMA+VEN. https://t.co/AFbisJwbTL
Most patients with ET can expect a normal life expectancy @MPN_Hub @MPN_RF https://t.co/7i7CDywd8O
Just published @JAMA_current our review on ET Don’t miss the podcast @JAMA_current @MayoHemeOnc @MayoMN_IMRES @NicoGagelmann @VincentRK #mpnsm Review: Essential Thrombocythemia https://t.co/MA7BoA3xOL
